NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings results on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to the consensus estimate of $26 million. Blueprint Medicines's revenue was up 4888.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.83) EPS. View Blueprint Medicines' Earnings History.

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Blueprint Medicines.

12 equities research analysts have issued 1 year price objectives for Blueprint Medicines' stock. Their forecasts range from $70.00 to $125.00. On average, they expect Blueprint Medicines' share price to reach $104.58 in the next year. This suggests a possible upside of 56.1% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

Press coverage about BPMC stock has been trending neutral recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Blueprint Medicines earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Blueprint Medicines.

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Nektar Therapeutics (NKTR), AbbVie (ABBV), Stratasys (SSYS), Canopy Growth (CGC), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Xilinx (XLNX) and STMicroelectronics (STM).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Westfield Capital Management Co. LP (1.57%), Eagle Asset Management Inc. (1.55%) and Perceptive Advisors LLC (1.26%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Victory Capital Management Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc. and Spark Investment Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

BPMC stock was purchased by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Jane Street Group LLC, Sectoral Asset Management Inc and Guggenheim Capital LLC. View Insider Buying and Selling for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $66.98.